The U.S. Food and Drug Administration (FDA) has given clearance to Neurent Medical’s NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT), a proprietary system which provides physicians access to the first in-office treatment for those suffering from chronic rhinitis. Chronic rhinitis, a condition that is marked by symptoms of congestion, runny nose, sneezing, and nasal itching caused by inflammation of the mucosal membrane, currently affects approximately one in four Americans. The NEUROMARK™ RNT system works by using a uniquely designed flexible electrode array geometry that allows access to posterior nasal nerves that are traditionally hard to reach and creates lesions to disrupt this nerve-tissue. The system also contains important features outside of its design, including its ability to integrate biofeedback monitoring and an advanced algorithm control that allows clinicians to simultaneously disrupt multiple nerves with an impressive level of precision without sacrificing patient comfort. Traditionally, this condition is treated in a trial-and-error manner, with medications and sprays that are ineffective or can only offer relief on a short-term basis. With chronic rhinitis proven to significantly affecting a patient’s quality of life, mental health, and general wellbeing, Neurent Medical is committed to lead efforts to provide innovative treatments for chronic inflammatory sino-nasal diseases to address patients’ unmet needs.  

Read more here